Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation...

Full description

Bibliographic Details
Main Authors: Ondrej Fiala, Jindrich Finek, Alexandr Poprach, Bohuslav Melichar, Jindrich Kopecký, Milada Zemanova, Katerina Kopeckova, Tomas Mlcoch, Tomas Dolezal, Lenka Capkova, Tomas Buchler
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
renal cell carcinoma
Memorial Sloan–Kettering Cancer Center risk
sunitinib
first line
outcome
Online Access:https://www.mdpi.com/2072-6694/12/4/808

Internet

https://www.mdpi.com/2072-6694/12/4/808

Similar Items